Objectives-To assess the yield of neck ultrasound (US) when serum thyroglobulin (Tg) is undetectable (<0.1 ng/mL) compared to elevated serum Tg in patients with differentiated papillary thyroid carcinoma (PTC) treated with thyroidectomy and radioactive iodine 131 (RAI) ablation.
P apillary thyroid carcinoma (PTC) is the most common cancer of the thyroid gland and affects an estimated 14.9 people per 100,000. 1 The standard of care for patients with PTC larger than 4 cm, gross extrathyroidal extension, or clinically apparent metastatic disease to nodes (N1) or distant sites (M1) is near-total or total thyroidectomy. 2 For patients with PTC larger than 1 cm but smaller than 4 cm without extrathyroidal extension and without clinical evidence of lymph node metastases, the initial surgical procedure can be either a bilateral procedure (near-total or total thyroidectomy) or a unilateral procedure (lobectomy). Near-complete and complete thyroidectomy is often followed by radioactive iodine 131 (RAI) ablation therapy, which destroys the residual normal thyroid (remnant ablation) and can be used to evaluate the completeness of surgical resection with a post-therapy whole-body scan. [2] [3] [4] Many patients then undergo serial neck ultrasound (US) examinations (imaging of the thyroid and lateral neck) with serum thyroglobulin (Tg) measurement to monitor for local recurrence. Serum Tg is a highly sensitive biomarker for recurrent disease in patients with differentiated PTC. [5] [6] [7] [8] However, it cannot be used as an effective marker when anti-Tg antibodies are present, as the antiTg antibodies can lead to falsely low serum Tg measurements. 2, 8, 9 Five percent to 20% of patients with differentiated thyroid cancer have local or regional recurrences, which in most cases are located within the neck. [10] [11] [12] The goal of postsurgical follow-up in these patients is the early discovery of persistent or recurrent disease. 13 Various imaging strategies exist to monitor for thyroid cancer recurrence, with high-resolution neck US considered the primary tool for the identification of locoregional thyroid cancer recurrence.
14 The American Thyroid Association generally recommends measuring serum Tg and anti-TG antibodies 6 to 12 months after RAI therapy and performing neck US examinations at 6-to 12-month intervals. 2, 4 In support of routine neck US surveillance, the revised American Thyroid Association guidelines state that minimal amounts of residual disease are often located in the neck, and performing neck US examinations in these patients offers the best opportunity to recognize or exclude neoplastic disease even when the serum Tg is undetectable. [15] [16] [17] There are few studies evaluating the rate of recurrence when the serum Tg is undetectable, with one recent study reporting that routine screening US identified recurrence in only 1 of 170 patients without signs of biochemical recurrence. 18 Moreover, the authors reported false-positive US abnormalities in 67% of patients (114 of 171) after therapy, leading to additional testing without identifying clinically significant disease.
Another important aspect of patient care to consider is anxiety related to false-positive results from neck US examinations performed when the serum Tg is undetectable. The impact of false-positive results from imaging related to cancer can be substantial. In a study of women with false-positive mammographic results, the authors found a statistically significant increase in antidepressant and anxiolytic initiation within 3 months of the false-positive results. 19 The impact of false-positive results from neck US when the probability of recurrence is very low is an essential consideration in this group, as the self-reported quality of life of thyroid cancer survivors is overall similar to or worse than that of survivors of other types of cancers, which is in part due to the fear and anxiety related to the possibility of cancer recurrence. 20 The purpose of this retrospective study was to determine whether neck US identified recurrent disease in patients with an undetectable serum Tg level after total thyroidectomy and RAI ablation for differentiated PTC. The results can be used to determine appropriate imaging surveillance for this subgroup of patients.
Materials and Methods
Institutional Review Board approval was obtained for this retrospective study. We conducted a retrospective chart review from January 2010 through December 2015 to identify patients with the following characteristics: (1) had a diagnosis of PTC; (2) underwent neartotal or total thyroidectomy; (3) showed no evidence of distant metastatic disease on initial imaging; (4) underwent RAI ablation therapy; (5) had postoperative serum Tg levels obtained, with negative anti-Tg antibody results; and (6) had postoperative US examinations within 6 months before or 6 months after the serum Tg level test. We reviewed the patients' imaging results, serum Tg levels, follow-up imaging, and pathologic results from biopsies performed. Serum Tg was measured with an immunoenzymatic assay (UniCel DxI immunoassay system; Beckman Coulter, Brea, CA) and is reported in nanograms per milliliter, with undetectable considered less than 0.1 ng/mL. The Tg antibody was measured by a chemiluminescence assay (Immulite 2000; Siemens Healthineers, Erlangen, Germany) and is reported in international units per milliliter. This retrospective review was limited to patients who had undergone near-total or total thyroidectomy followed by RAI ablation to evaluate the added value of neck US examinations when performed concurrently with serum Tg measurement. It is not the standard of care at our institution to perform bilateral thyroidectomy with RAI ablation for all patients with PTC.
Neck US examinations were performed in the Department of Radiology by experienced sonographers using either an Epiq 7 system (Philips Healthcare, Bothell, WA) equipped with a commercially available 5-12-MHz linear transducer or an S2000 Helix system (Siemens Healthineers) equipped with a commercially available 5-12-MHz linear transducer. The standard post-thyroidectomy protocol included imaging of levels 1 through 7 bilaterally with cine clips in the transverse and sagittal planes. Static images of representative lymph nodes were obtained at each level with and without measurements in the transverse and sagittal planes. Any abnormal findings or lymph nodes were also imaged with color Doppler flow and additional cine images. Neck US examinations were performed in all patients before US-guided fine needle aspiration (FNA), which was also performed in the Department of Radiology by experienced radiologists using either 25-or 22-gauge needles.
For the statistical analysis, categorical data were summarized by frequency distributions (ie, counts) and relative frequency distributions (ie, percentages). The statistical comparison of the yield of US for detection of recurrent thyroid cancer when serum markers were normal versus when they were elevated was based on the Fisher exact test. The 2-sided P < .05 null hypothesis decision rule was the criterion for rejecting the null hypothesis that the yield of US for detection of recurrent thyroid cancer was the same for patients with normal and elevated serum marker (serum Tg) levels.
Results
Our initial search identified 363 patients, of whom 245 were excluded because serum Tg was not measured postoperatively; US examinations were not performed postoperatively; RAI ablation was not performed; or they had positive Tg antibody results. Of the remaining 118 patients, 53 had only undetectable serum Tg levels postoperatively, 23 had both undetectable and elevated serum Tg levels postoperatively, and 42 had persistently elevated serum Tg levels postoperatively. Patient demographics, tumor characteristics, and staging information are provided in Table 1 .
There were 76 patients who had differentiated PTC, underwent thyroidectomy and RAI ablation therapy after thyroidectomy, and had undetectable serum Tg levels (<0.1 ng/mL) in the absence of Tg antibodies. These patients underwent a total of 257 thyroid bed/neck US examinations between April 2010 and April 2017, ranging from 1 to 8 postoperative/post-RAI neck US examinations for an individual patient. Of these 257 examinations, there were 19 examinations (7.4%) in 18 (23.7%) patients in which the serum Tg level was undetectable, and US raised the possibility of disease recurrence. Six examinations had findings of possible recurrence in the thyroidectomy bed, 1 in the thyroid cartilage, and 12 in neck lymph nodes. None of these 18 patients had recurrent disease by pathologic analysis or clinical follow-up of at least 1 year. Eight patients underwent US-guided FNA with resultant benign pathologic results (7 lymph nodes and 1 lesion in the thyroidectomy bed); 9 patients had follow-up neck US examinations that showed stability of findings; and 1 patient had clinical follow-up without additional imaging. One of the patients in this group had recurrent PTC identified by US and confirmed by FNA when the serum Tg level was elevated. There were 65 patients who had differentiated PTC, underwent thyroidectomy and RAI ablation therapy after thyroidectomy, and had elevated serum Tg levels (>0.1 ng/mL) in the absence of Tg antibodies. These patients underwent a total of 196 thyroid bed/neck US examinations between April 2010 and April 2017, ranging from 1 to 9 postoperative/post-RAI neck US examinations for an individual patient. Of these 196 examinations, there were 24 examinations (12.2%) in 22 (33.8%) patients in which the serum Tg level was elevated, and US raised the possibility of disease recurrence. Ten examinations had findings of possible recurrence in the thyroidectomy bed, 13 in neck lymph nodes, and 1 in both the thyroidectomy bed and neck lymph nodes. Of these 22 patients, 12 underwent US-guided FNA, with 9 patients showing PTC (4 in the thyroidectomy bed and 5 in neck lymph nodes); 7 patients had follow up neck US examinations that showed stability of findings; and 3 patients were lost to follow-up. Recurrence was observed primarily in patients who always had elevated serum Tg levels postoperatively (n 5 8), as opposed to patients who had both elevated and undetectable serum Tg levels postoperatively (n 5 1). The yield of neck US was significantly lower when patients had an undetectable serum Tg level compared to when the serum Tg level was elevated (P 5 .001, Fisher exact test).
Discussion
According to the revised American Thyroid Association thyroid cancer guidelines, a neck US examination to Epstein et al-Neck US of Papillary Thyroid Carcinoma With an Undetectable Serum Tg Level evaluate the thyroid bed and neck node compartments should be performed 6 to 12 months after initial surgery and then periodically, depending on the patient's risk of recurrence and serum Tg status. 2 In these guidelines, "Low-risk patients who have remnant ablation, negative neck US, and a low serum Tg on thyroid hormone therapy in a sensitive assay (<0.2 ng/mL) or after thyrotropin stimulation can be followed primarily with clinical examination and serum Tg measurements on thyroid hormone replacement." The results of this retrospective study support the elimination of neck US as part of routine surveillance of patients with differentiated PTC and an undetectable serum Tg level. Neck US did not identify recurrent PTC when the serum Tg level was undetectable on a highly sensitive assay in patients who underwent total thyroidectomy and RAI therapy. Nearly all (91.2%) neck US examinations in this subgroup yielded negative findings for abnormalities, and although 19 examinations raised the possibility of recurrence, no recurrences were identified by FNA or follow-up of at least 1 year.
Most thyroid bed nodules identified by neck US are benign lesions caused by postoperative fibrosis or suture granulomas (Figure 1 ).
14 In a study evaluating US findings in the surgical bed after thyroidectomy in which serum Tg was not used to screen patients at risk for recurrence, 64% of abnormal lesions biopsied with FNA (36 of 56 lesions) were benign, including remnant thyroid tissue, postoperative fibrosis, suture granuloma, strap muscle with a nodular contour, reactive lymph nodes, cysts, tracheal cartilage, and fat necrosis ( Figure  2) . 21 Another study determined the sensitivity and specificity of various imaging characteristics of lymph nodes corresponding to malignancy but did not use serum Tg as a discriminatory parameter (Figures 3-5) .
We identified only 3 studies that specifically reported on recurrent PTC with an undetectable serum Tg level. One study found that 3 of 250 patients (1.2%) had recurrence with an undetectable serum Tg level after recombinant human thyrotropin stimulation but used a substantially less-sensitive serum Tg assay with a discriminatory value of 1 ng/mL. 13 The second was a case series of 5 patients with recurrence and undetectable serum Tg levels, but only 3 of the recurrences were in the neck, and none were identified by neck US. 8 In the third study, surveillance neck US found recurrence in only 1 of 170 patients without biochemical signs of recurrence. 18 Our results suggest that an undetectable serum Tg level measured by a highly sensitive assay predicts a very low rate of local recurrence and could be used to discriminate which patients should undergo neck US surveillance.
A study of the natural history of thyroid bed nodules detected during neck US examinations in patients with differentiated thyroid cancer determined that most nodules do not show clinically significant growth over several years of follow-up.
14 Over a median clinical follow-up of 5 years, only 9% (17 of 191) of patients had increases in the size of thyroid bed nodules, with a mean growth rate of 1.3 mm per year. The risk of lymph node recurrence is low (<2%) in patients with differentiated thyroid cancer and a low or undetectable serum Tg level, and the benefits of early discovery (<8-10 mm) have not been demonstrated. 2 Given these results coupled with the results from our study, clinicians and patients who are not comfortable eliminating neck US when the serum Tg level is undetectable on a highly sensitive assay could opt for imaging surveillance every 5 years. Our recommendations to eliminate or reduce the frequency of US surveillance when the serum Tg level is undetectable are similar to the European Thyroid Association guidelines, which state that annual US is not necessary in very low-risk and low-risk patients with undetectable serum Tg levels, and a final US scan can be performed at 5 to 7 years, combined with a serum Tg measurement if the first period of follow-up did not show clinical, US, or biochemical abnormalities. 22 The revised American Thyroid Association guidelines provide specific recommendations about when to biopsy according to neck US findings. With regard to lymph nodes, recommendation 65(C) states that suspicious lymph nodes of less than 8 to 10 mm in the smallest dimension may be followed without biopsy, with consideration for biopsy or intervention if there is growth or if the node threatens a vital structure. 2 Three patients in our study could have avoided US-guided biopsy based on this recommendation, as the lymph nodes biopsied were less than 8 mm in the smallest dimension (Figures 3-5) . We did not evaluate why these patients underwent US-guided biopsy rather than continued surveillance.
One of the limitations of this study was a small sample size from a single academic institution. The number of patients who met inclusion criteria was limited by the lack of serum Tg measurements, no postoperative neck US examinations, and the timing of the serum Tg measurements relative to neck US examinations. A limitation related to biopsy results is that the aspirates from USguided biopsy of neck lymph nodes were not routinely sent for Tg wash-out, which has been reported to increase diagnostic accuracy when combining cytologic results with Tg wash-out. 23 Seven of the 8 lesions biopsied in the undetectable serum Tg group were lymph nodes. Additionally, 10 patients initially had neck US findings that raised the possibility of recurrence but did not undergo US-guided biopsy. It is possible that some of these patients had recurrent disease despite negative cytologic findings or reassuring clinical/imaging followup. However, these patients were ultimately treated as if they did not have recurrent disease and that the abnormal on neck US findings were unlikely to represent recurrent disease, which supports the conclusion that neck US does not improve the ability to detect recurrent disease in the context of an undetectable serum Tg level.
Our study only examined patients with differentiated PTC treated with near-complete or complete thyroidectomy and RAI ablation with undetectable serum Tg levels. Our results cannot be generalized to patients with other types of thyroid cancer or patients who have not undergone near-total or total thyroidectomy with RAI ablation therapy. Moreover, our results cannot be generalized to patients with differentiated thyroid cancers that undergo dedifferentiation.
